Community-Based Seroprevelance of SARS-CoV-2 in Saudi Arabia

Introduction  The new coronavirus disease 2019 (COVID-19) is a major global concern. Due to the number of asymptomatic cases that go untested, the actual proportion of those who have been infected is likely to be higher than the reported prevalence. Thus, investigating the exact proportion of those...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-12, Vol.14 (12), p.e32419-e32419
Main Authors: Alassaf, Lujain, Almudarra, Sami, Almudaiheem, Abdullah, Almutlaq, Hind, Alqunaibet, Ada, Alseraihi, Haleemah, Alaswad, Rehab, Khoja, Abdullah T, AlAbdulkareem, Khaled, AlSaif, Faisal, Abu Saris, Raghib
Format: Article
Language:English
Subjects:
Antibodies
Asymptomatic
Coronaviruses
COVID-19
Cross-sectional studies
Disease prevention
Disease transmission
Epidemiology/Public Health
Foreign residents
Immunoglobulins
Infections
Infectious Disease
Males
Public Health
Sample size
Sampling techniques
Serology
Severe acute respiratory syndrome coronavirus 2
Viruses
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction  The new coronavirus disease 2019 (COVID-19) is a major global concern. Due to the number of asymptomatic cases that go untested, the actual proportion of those who have been infected is likely to be higher than the reported prevalence. Thus, investigating the exact proportion of those who developed antibodies against the virus through serological surveys is crucial to identify the immune status of the population and direct public health decisions accordingly. Objectives The aim of this study is to estimate the seroprevalence of SARS-CoV-2 in the community and to describe the epidemiological characteristics of the discovered cases. Methods Between July and October 2020, a cross-sectional sero-survey was conducted including a total of 15,873 serum samples collected from seven regions within the kingdom. Using a multistage convenient sampling, people were invited to participate in an interviewer-administrated questionnaire. Afterward, blood samples were collected and seroprevalence was determined using the SARS-CoV-2 virus IgG/IgM antibody detection kits (ELISA). A p-value of
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.32419